Clinical Trials Logo

Hookworm Disease clinical trials

View clinical trials related to Hookworm Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03373214 Completed - Hookworm Infection Clinical Trials

Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults

Start date: February 1, 2018
Phase: Phase 1
Study type: Interventional

Na-GST-1 is a protein expressed during the adult stage of the Necator americanus hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination with recombinant Na-GST-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of administering Na-GST-1 with or without the CpG 10104 immunostimulant to healthy Gabonese adults living in an area of endemic hookworm infection.

NCT ID: NCT02839161 Completed - Hookworm Infection Clinical Trials

Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children

Start date: January 2017
Phase: Phase 1
Study type: Interventional

Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon. Children will receive three doses of the Na-GST-1/Alhydrogel hookworm vaccine co-administered with the Na-APR-1 (M74)/Alhydrogel hookworm vaccine or the hepatitis B vaccine co-administered with sterile saline. All injections will be delivered intramuscularly (deltoid) on approximately Days 0, 56, and 112 or 180.

NCT ID: NCT02476773 Completed - Hookworm Infection Clinical Trials

Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults

Start date: January 2016
Phase: Phase 1
Study type: Interventional

Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination wtih recombinant GST-1 or APR-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy Brazilian adults living in an area of endemic hookworm infection.

NCT ID: NCT02143518 Completed - Hookworm Infection Clinical Trials

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Start date: October 2014
Phase: Phase 1
Study type: Interventional

Na-GST-1 is a protein expressed during the adult stage of the hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination with recombinant GST-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of two formulations of Na-GST-1 in healthy adult volunteers when co-administered with the immunostimulant CpG 10104, a Toll-like Receptor-9 agonist.

NCT ID: NCT02126462 Completed - Hookworm Infection Clinical Trials

Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults

Start date: November 2014
Phase: Phase 1
Study type: Interventional

Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination with recombinant GST-1 or APR-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy Gabonese adults living in an area of endemic hookworm infection.

NCT ID: NCT01717950 Completed - Hookworm Infection Clinical Trials

Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

Start date: September 2013
Phase: Phase 1
Study type: Interventional

Hookworms digest hemoglobin from erythrocytes for use as an energy source via a proteolytic cascade that begins with the aspartic protease, APR-1. Vaccination with recombinant APR-1 has protected animals from infection in challenge studies. This study will evaluate the safety and immunogenicity of two formulations of Na-APR-1 (M74) in healthy adult volunteers when co-administered with different concentrations of the immunostimulant GLA-AF.

NCT ID: NCT01385189 Completed - Hookworm Infection Clinical Trials

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Start date: May 2012
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety, reactogenicity, and immunogenicity of Na-GST-1 adsorbed to Alhydrogel® with or without two different dose concentrations of a novel adjuvant, GLA-AF (1 µg or 5 μg) among healthy adult volunteers.

NCT ID: NCT01261130 Completed - Hookworm Infection Clinical Trials

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This two part study will evaluate the safety and immunogenicity of two formulations of Na-GST-1, first in hookworm-naïve individuals using an open-label design, and then in adults living in an area of endemic hookworm infection using a randomized, double-blind design. The two formulations to be evaluated are Na-GST-1 adsorbed to an adjuvant, Alhydrogel®, and Na-GST-1 adsorbed to Alhydrogel® and administered with GLA-AF.